Roche's Vamikibart: Sustained Phase III Benefit, but a Regulatory Evidence Question Remains

On October 10, Roche announced new 52-week results from its Phase III MEERKAT and SANDCAT trials evaluating intravitreal vamikibart, an anti-IL-6 monoclonal antibody, in patients with uveitic macular edema.

The company reported sustained improvements in visual acuity and retinal thickness, with approximately two-thirds of eligible patients requiring no additional treatment after the initial 16-week period.

The FDA has accepted Roche's Biologics License Application, with an approval decision expected by July 2027. Regulatory submissions have also been accepted in the European Union, China, and Japan. Roche

Primary source: Roche — October 10 Phase III announcement

Why it matters strategically

There is an important qualification that deserves more attention than the headline.

The original 16-week primary endpoint was statistically significant in MEERKAT but not statistically significant in SANDCAT.

Roche disclosed this difference in October 2025.

The new 52-week data reinforce the durability of treatment effects but do not retroactively establish statistical significance for the previously unsuccessful primary endpoint.

This distinction matters for regulatory interpretation.

Durable efficacy is not necessarily equivalent to confirmatory efficacy.

The FDA must evaluate the totality of evidence, including the consistency of treatment effects across studies, dose selection, clinical relevance, and safety.

Vamikibart could become an important non-steroidal treatment option, potentially reducing reliance on corticosteroids associated with cataracts and elevated intraocular pressure.

However, the commercial thesis also depends on whether treatment benefits justify intravitreal administration, monitoring requirements, and expected pricing.